anti-CD3/undisclosed target bispecific T-cell engager (Micromet/Boehringer Ingelheim/Amgen)

N/A

Report date: 2026/03/19 16:58:18

Base Information

Drug Nameanti-CD3/undisclosed target bispecific T-cell engager (Micromet/Boehringer Ingelheim/Amgen)
Drug Alias NameBiTe antibodies (Amgen)BiTe antibodies (Amgen/sanofi-aventis)BiTe antibodies (Micromet/Sanofi)BiTe antibodies (Micromet/sanofi-aventis)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulators
TargetsT cell surface glycoprotein CD3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFrance
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAmgen Rockville Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofiAmgen IncAmgen Rockville Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A